药效团
化学
止痛药
药理学
兴奋剂
类阿片
伤害
受体
生物活性
阿片受体
G蛋白偶联受体
外围设备
吗啡
部分激动剂
阿片肽
内在活性
神经肽
脑啡肽
结构-活动关系
痛觉过敏
μ-阿片受体
作者
Mengna Zhang,Jie Gao,Jiamin Feng,Zefei Wang,Xia Wang,Zixiao Wang,Bowen Yu,Yongpeng Liu,Sha Hu,Biao Xu,Ning Li,高飞云,Quan Fang
标识
DOI:10.1021/acs.jmedchem.6c01096
摘要
This study establishes a two-step strategy for developing triazole-stapled multifunctional agonists that integrate opioid and neuropeptide FF (NPFF) pharmacophores. Initially, calcium mobilization assays, enzymatic stability tests, and analgesic activity screens identified triazole-stapled opioid peptide 16, derived from the opioid pharmacophore of the multifunctional opioid/NPFF agonist DN-9. Subsequently, chimeric conjugation of 16 with the NPFF pharmacophore yielded the novel multitarget analgesic agonist, 16a. Functional assays demonstrated that 16 functions as a μ-opioid receptor (MOR) agonist and a δ-opioid receptor partial agonist, while 16a exhibits multitarget activity at MOR, κ-opioid receptor, and NPFF receptors, with G-protein-biased signaling at MOR. Pharmacological evaluations revealed that subcutaneous administration of both compounds elicited sustained dose-dependent antinociceptive effects across acute and visceral pain models. Notably, these compounds exhibited diminished propensity for addiction and respiratory depression and furthermore produced nontolerant antinociception via an NPFF receptor-independent pathway. This strategy offers a promising framework for developing long-lasting analgesics.
科研通智能强力驱动
Strongly Powered by AbleSci AI